650 results on '"Moliterno, David"'
Search Results
2. Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI
3. Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-Analysis
4. Coronary Physiology Assessment
5. Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention
6. Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS Registry
7. Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention
8. LB-9 | Repeated Coronary Revascularization in High-Risk Patients Treated With Ticagrelor Monotherapy After PCI: Insights from the Randomized TWILIGHT Trial
9. JACC Journals’ Pathway Forward With AI Tools
10. Immediate vs Delayed Coronary Angiography for Out-of-Hospital Cardiac Arrest
11. Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS Registry
12. Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention: The PARIS Registry
13. Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents
14. Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention: Results From the PARIS Registry
15. Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study
16. Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention: Insights From the PARIS Registry
17. Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk: A Cost Consequence Simulation From PARIS
18. Toward a More Interactive Central Illustration
19. Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index
20. TCT-13 Ticagrelor Monotherapy in Patients With Peripheral Artery Disease Undergoing PCI
21. Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective–2018 Update
22. Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: Results From the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients)
23. Abstract 17006: Tradeoff in Risks for Myocardial Infarction and Bleeding in Relation to Bleeding Risk: Insights From PARIS Registry
24. Ticagrelor monotherapy after PCI in high-risk patients with prior MI : A prespecified TWILIGHT Substudy
25. White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry)
26. Drug–Drug Interactions in Cardiovascular Catheterizations and Interventions
27. JACC: Cardiovascular Interventions Top Reviewers 2021
28. Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI
29. TCT-39 Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index: TWILIGHT-BMI Analysis
30. Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR
31. The Case for Mandatory COVID-19 Vaccination of Health Care Workers
32. Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD
33. Coronary Physiology Assessment: On Becoming Faster, Friendlier, and a Better Guiding Companion
34. In-Hospital and 1-Year Outcomes Among Percutaneous Coronary Intervention Patients With Chronic Kidney Disease in the Era of Drug-Eluting Stents: A Report From the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) Registry
35. JACC Journals' Pathway Forward With AI Tools: The Future Is Now.
36. ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents
37. QRS duration predicts death and hospitalization among patients with atrial fibrillation irrespective of heart failure: evidence from the AFFIRM study
38. Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention
39. Improving the Design of Future PCI Trials for Stable Coronary Artery Disease: JACC State-of-the-Art Review
40. In Unstable Angina or Non–ST-Segment Acute Coronary Syndrome, Should Patients With Multivessel Coronary Artery Disease Undergo Multivessel or Culprit-Only Stenting?
41. Prevention of Premature Discontinuation of Dual Antiplatelet Therapy in Patients With Coronary Artery Stents: A Science Advisory From the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, With Representation From the American College of Physicians
42. Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS
43. TCT CONNECT-64 Impact of DAPT Cessation in High Bleeding-Risk Patients Undergoing PCI: Insights From the PARIS Registry
44. Evidence for substantial effect modification by gender in a large-scale genetic association study of the metabolic syndrome among coronary heart disease patients
45. Premature myocardial infarction novel susceptibility locus on chromosome 1p34-36 identified by genomewide linkage analysis
46. Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial
47. Increased mortality among patients taking digoxin—analysis from the AFFIRM study
48. JACCJournals’ Pathway Forward With AI Tools
49. The Influence of Peripheral Arterial Disease on Outcomes: A Pooled Analysis of Mortality in Eight Large Randomized Percutaneous Coronary Intervention Trials
50. Third universal definition of myocardial infarction
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.